John M. Evans, CEO at Beam Therapeutics Inc. (BEAM), sold 97,094 shares at $29.19 ($2.8M) on 2026-01-29, disclosed to the SEC on 2026-02-02.
Open-market sale of $2.8M BEAM by CEO. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $29.19 | 16,333 | $477K | 17.0% |
| 2 | $29.19 | 16,333 | $477K | 17.0% |
| 3 | $29.74 | 8,667 | $258K | 9.2% |
| 4 | $29.74 | 8,667 | $258K | 9.2% |
| 5 | $28.27 | 22,094 | $625K | 22.3% |
| 6 | $28.27 | 22,094 |
| $625K |
| 22.3% |
| 7 | $29.00 | 2,906 | $84K | 3.0% |
| Total | $28.87 avg | 97,094 | $2.8M | 100% |
| Filing → |
| BEAM | SELL | 2026-04-06 | $739K | — | Filing → |
| BEAM | SELL | 2026-04-01 | $1.1M | — | Filing → |
| BEAM | SELL | 2025-10-03 | $1.2M | — | Filing → |